← Back to Search

Azithromycin 500mg for Premature Rupture of Membranes (ADAPT Trial)

Phase 4
Waitlist Available
Led By Rupsa C Boelig, MD
Research Sponsored by Thomas Jefferson University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

ADAPT Trial Summary

This trial is to assess how well azithromycin works in pregnant women with PPROM.

Eligible Conditions
  • Premature Rupture of Membranes

ADAPT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Azithromycin trough in amniotic fluid
Secondary outcome measures
Histologic chorioamnionitis
IL-6 in amniotic fluid
IL-8 in cord blood
+5 more

ADAPT Trial Design

2Treatment groups
Active Control
Group I: Azithromycin 500mgActive Control1 Intervention
500mg azithromycin PO daily for seven days
Group II: Azithromycin 1000mgActive Control1 Intervention
1000mg azithromycin PO once at admission

Find a Location

Who is running the clinical trial?

Christiana Care Health ServicesOTHER
114 Previous Clinical Trials
105,645 Total Patients Enrolled
Thomas Jefferson UniversityLead Sponsor
444 Previous Clinical Trials
145,618 Total Patients Enrolled
Rupsa C Boelig, MDPrincipal InvestigatorThomas Jefferson University
4 Previous Clinical Trials
431 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Apr 2025